Navigation Links
iBio Announces Production of Biosimilar Palivizumab with its iBioLaunch™ Technology
Date:4/10/2012

NEWARK, Del., April 10, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) announced that its proprietary iBioLaunch™ technology for the production of biotherapeutic proteins and vaccine antigens in whole green plants has been used to produce a functional monoclonal antibody copy of palivizumab, a humanized monoclonal antibody that binds to respiratory syncytial virus (RSV) glycoprotein fusion protein (F), and inhibits viral entry into cells. Palivizumab is used to reduce RSV associated hospitalizations, but its high cost limits treatment to high-risk infants who receive monthly intramuscular injections throughout the RSV season. Worldwide annual sales of palivizumab exceed $900 million.

Scientists at iBio's research and development partner, Fraunhofer USA Center for Molecular Biotechnology, have expressed the antibody heavy and light chains in green tissues of plants using an iBioLaunch vector system developed for multi-chain proteins such as antibodies. The expression of palivizumab in plants resulted in self-assembly of the appropriate antibody quaternary structure, which was then recovered from the plant tissue.

iBioLaunch-produced palivizumab was shown to bind inactivated RSV, indicating that it recognizes F antigen presented on the virus' surface. Furthermore, plant-produced palivizumab was demonstrated to have a dose-dependent RSV neutralizing activity in a plaque reduction neutralization test. The effective concentration to observe 50% plaque reduction is comparable for plant-produced palivizumab to that reported for palivizumab manufactured in recombinant mammalian cells. The virus neutralizing activity observed is specific to palivizumab, as demonstrated with the use of an unrelated, plant-produced monoclonal antibody as a negative control for any plant-specific activity.

The production of functional palivizumab in plants extends the number of monoclonal antibodies that have been produced using the iBioLaunch™ system. All the monoclonal antibodies manufactured using iBioLaunch technology have been shown to be correctly assembled and fully active in appropriate bioassays.

About iBio, Inc.iBio develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; enables rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production. Further information is available at: www.ibioinc.com.

Forward-Looking StatementsStatements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.Contacts:Corporate:Investor:Robert Erwin, PresidentDouglas BeckiBio, Inc.iBio, Inc.302-355-2335302-355-0923rerwin@ibioinc.comir@ibioinc.com


'/>"/>

SOURCE iBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SafeWire, LLC. Announces first US product launch of Y-wire™
2. Sunpeaks Ventures Announces Letter of Intent to Export Clotamin to Top Russian Pharmacies
3. Rapid Fire Marketing Announces the First Shipment of its Vapor Inhaler Model Named the CannaCig Has Passed All Patient Tests; Second Round of Production to Start This Week
4. Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores
5. Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2012 Results
6. BioNeutral Group Announces Positive Results for the Ygiene 206 Sterilization Tests
7. Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
8. BONESUPPORTS New CEO Announces 100 Day Plan
9. Sunpeaks Ventures Announces Agreement with Albeck Financial Services
10. Psyche Systems Announces Availability of MicroPath, the First LIS for Microbiology
11. Net Medical Xpress Announces 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ORLANDO, Fla. , July 17, 2017  MedX ... - branded medical testing, strengthening and rehabilitation equipment, today ... Back Machine Program. MedX is considered the gold standard ... world leader in specialized medical strengthening equipment. ... into a lease with the physician or practice who ...
(Date:7/13/2017)... 2017  Centurion Medical Products, a leader in medical product innovation ... impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are part of ... patient pain while preventing unneeded emergency department admission due to severe ...
(Date:7/12/2017)... , July 12, 2017  Eli Lilly and Company ... agreement with generic companies to resolve pending patent litigation in ... Virginia regarding the Cialis ® (tadalafil) ... on April 26, 2020. As part of the agreement, Cialis ... September 27, 2018. "The unit dose patent for ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The Bryant Agency, a ... and business owners in the Dalton region, is working in conjunction with the ... assault and physical abuse. , The GreenHouse is headquartered in Dalton and provides ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... financial planning services to communities in the greater Birmingham area, is joining the ... to underprivileged young people in the region. , The Chris Hammond Youth Foundation ...
(Date:7/21/2017)... Norwalk, Connecticut (PRWEB) , ... July 21, 2017 , ... ... data from HealthCareMandA.com . The number of hospital acquisitions rose to 23 in ... quarter of 2017, and up 15% from the 20 announced deals in the year-ago ...
(Date:7/21/2017)... Basking Ridge, NJ (PRWEB) , ... July 21, ... ... Hills (VNA) has received a $5,000 grant from the C. R. ... Adult Day Center at Somerset Hills , a service available through the ...
(Date:7/21/2017)... Fresno, CA (PRWEB) , ... July 21, 2017 , ... ... Ms. “Tu” Tuantu Doan Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join ... than 27 years of experience in dermatology, skin cancer , and more. She ...
Breaking Medicine News(10 mins):